Cargando…
Intraperitoneal delivery of a novel drug‐like compound improves disease severity in severe and intermediate mouse models of Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder that causes progressive muscle weakness and is the leading genetic cause of infant mortality worldwide. SMA is caused by the loss of survival motor neuron 1 (SMN1). In humans, a nearly identical copy gene is present,...
Autores principales: | Osman, E. Y., Rietz, A., Kline, R. A., Cherry, J. J., Hodgetts, K. J., Lorson, C. L., Androphy, E. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367425/ https://www.ncbi.nlm.nih.gov/pubmed/30733501 http://dx.doi.org/10.1038/s41598-018-38208-9 |
Ejemplares similares
-
Short-duration splice promoting compound enables a tunable mouse model of spinal muscular atrophy
por: Rietz, Anne, et al.
Publicado: (2020) -
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds
por: Cherry, Jonathan J, et al.
Publicado: (2013) -
A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy
por: Monani, Umrao R., et al.
Publicado: (2003) -
The Proteome Signatures of Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap
por: Brown, Sharon J., et al.
Publicado: (2022) -
Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy
por: Comley, Laura H, et al.
Publicado: (2022)